Pimicotinib（ABSK021）
Phase 3Small molecule
Pimicotinib（ABSK021） is one of 12 small molecule programs targeting Giant Cell Tumor. It is currently in Phase 3.
1
Indications
2
Total Trials
1
Active Trials
11
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
14 competitors in Giant Cell Tumor
#DrugCompanyPhaseTrials
1IC-Green
CCHX Technologies Inc.
Approved
Zometa
PfizerPhase 3
Turalio
Daiichi SankyoPhase 2
Xgeva
Jiangsu Hansoh Pharmaceutical Co., Ltd.Approved
Tasigna
AAzurity Pharmaceuticals
Phase 2
Emactuzumab
RochePhase 3
Narlumosbart
SShanghai JMT-Bio Inc.
Phase 3
Prolia
AmgenPreclinical
Romvimza
DDeciphera Pharmaceuticals, LLC
Phase 2
Pimicotinib（ABSK021）
AAbbisko Therapeutics Co, Ltd
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Pimicotinib（ABSK021）. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- AAbbisko Therapeutics Co, Ltd